苯氧苄胺治疗前列腺肥大。一项双盲研究。

Phenoxybenzamine in prostatic hypertrophy. A double-blind study.

作者信息

Ferrie B G, Paterson P J

出版信息

Br J Urol. 1987 Jan;59(1):63-5. doi: 10.1111/j.1464-410x.1987.tb04581.x.

DOI:10.1111/j.1464-410x.1987.tb04581.x

Abstract

Forty-five patients awaiting prostatectomy participated in a double-blind study of phenoxybenzamine 10 mg/day for 5 weeks. Objective measurements of peak urine flow, voided volume, residual urine and frequency of micturition and nocturia showed no significant difference between phenoxybenzamine and placebo. Patients taking phenoxybenzamine had a significantly greater improvement in hesitancy and flow symptoms than those on placebo. Side effects occurred in 47.6% of patients on phenoxybenzamine and 22.2% of those on placebo. In this study phenoxybenzamine 10 mg/day was ineffective in patients with benign prostatic hypertrophy.

摘要

45名等待前列腺切除术的患者参与了一项双盲研究，服用苯苄胺，剂量为每日10毫克，持续5周。对最大尿流率、排尿量、残余尿量以及排尿和夜尿频率的客观测量结果显示，苯苄胺组与安慰剂组之间无显著差异。与服用安慰剂的患者相比，服用苯苄胺的患者在排尿犹豫和尿流症状方面有显著更大的改善。服用苯苄胺的患者中47.6%出现了副作用，服用安慰剂的患者中这一比例为22.2%。在本研究中，每日10毫克的苯苄胺对良性前列腺增生患者无效。